Fulcrum Therapeutics Reports Positive Initial Results from Trial of Pociredir in Sickle Cell Disease; Shares Surge Pre-Bell

MT Newswires Live12-08

Fulcrum Therapeutics (FULC) on Saturday reported positive initial results from its ongoing 20 mg dose cohort of the phase 1b PIONEER trial of pociredir in adult patients with sickle cell disease.

The company said that it observed clear dose-response, with a robust and clinically meaningful fetal hemoglobin induction at week 6 and mean absolute fetal hemoglobin in the 20 mg cohort increasing 9.9% at week 6 versus 5.6% in the 12 mg cohort.

The company further said that pociredir continued to be generally well-tolerated, with no treatment-related serious adverse events.

Fulcrum Therapeutics' share price jumped over 63% in recent Monday premarket activity.

Price: 14.55, Change: +5.65, Percent Change: +63.48

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589332400?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 19:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589332400","market":"hk","top_or_hot":-1,"title":"Fulcrum Therapeutics Reports Positive Initial Results from Trial of Pociredir in Sickle Cell Disease; Shares Surge Pre-Bell","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/FULC\">Fulcrum Therapeutics</a> (FULC) on Saturday reported positive initial results from its ongoing 20 mg dose cohort of the phase 1b PIONEER trial of pociredir in adult patients with sickle cell disease.</p><p>The company said that it observed clear dose-response, with a robust and clinically meaningful fetal hemoglobin induction at week 6 and mean absolute fetal hemoglobin in the 20 mg cohort increasing 9.9% at week 6 versus 5.6% in the 12 mg cohort.</p><p>The company further said that pociredir continued to be generally well-tolerated, with no treatment-related serious adverse events.</p><p>Fulcrum <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' share price jumped over 63% in recent Monday premarket activity.</p><p>Price: 14.55, Change: +5.65, Percent Change: +63.48</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fulcrum Therapeutics Reports Positive Initial Results from Trial of Pociredir in Sickle Cell Disease; Shares Surge Pre-Bell</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFulcrum Therapeutics Reports Positive Initial Results from Trial of Pociredir in Sickle Cell Disease; Shares Surge Pre-Bell\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-08 19:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/FULC\">Fulcrum Therapeutics</a> (FULC) on Saturday reported positive initial results from its ongoing 20 mg dose cohort of the phase 1b PIONEER trial of pociredir in adult patients with sickle cell disease.</p><p>The company said that it observed clear dose-response, with a robust and clinically meaningful fetal hemoglobin induction at week 6 and mean absolute fetal hemoglobin in the 20 mg cohort increasing 9.9% at week 6 versus 5.6% in the 12 mg cohort.</p><p>The company further said that pociredir continued to be generally well-tolerated, with no treatment-related serious adverse events.</p><p>Fulcrum <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' share price jumped over 63% in recent Monday premarket activity.</p><p>Price: 14.55, Change: +5.65, Percent Change: +63.48</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2589332400","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589332400","pubTimestamp":1765193477,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Fulcrum Therapeutics  on Saturday reported positive initial results from its ongoing 20 mg dose cohort of the phase 1b PIONEER trial of pociredir in adult patients with sickle cell disease.The company said that it observed clear dose-response, with a robust and clinically meaningful fetal hemoglobin induction at week 6 and mean absolute fetal hemoglobin in the 20 mg cohort increasing 9.9% at week 6 versus 5.6% in the 12 mg cohort.The company further said that pociredir continued to be generally well-tolerated, with no treatment-related serious adverse events.Fulcrum Therapeutics' share price jumped over 63% in recent Monday premarket activity.Price: 14.55, Change: +5.65, Percent Change: +63.48","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","FULC":"Fulcrum Therapeutics"},"translate_title":"Fulcrum Therapeutics报告了Pociredir治疗镰状细胞病试验的积极初步结果；盘前股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FULC":1.5},"content_text":"Fulcrum Therapeutics (FULC) on Saturday reported positive initial results from its ongoing 20 mg dose cohort of the phase 1b PIONEER trial of pociredir in adult patients with sickle cell disease.The company said that it observed clear dose-response, with a robust and clinically meaningful fetal hemoglobin induction at week 6 and mean absolute fetal hemoglobin in the 20 mg cohort increasing 9.9% at week 6 versus 5.6% in the 12 mg cohort.The company further said that pociredir continued to be generally well-tolerated, with no treatment-related serious adverse events.Fulcrum Therapeutics' share price jumped over 63% in recent Monday premarket activity.Price: 14.55, Change: +5.65, Percent Change: +63.48","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589332400","isCrawlerRequest":true}